BioPharma Dive - Latest News

Amgen obesity drug on hold; Regeneron sets first dividend

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.”  

Feb 9, 2025 - 21:44
 0
Amgen obesity drug on hold; Regeneron sets first dividend

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.”

 

Read More

Tags:

Previous Article

Novo outlines new late-stage study of obesity drug CagriSema

Next Article

AI tool helps find life-saving medicine for rare disease

Related Posts

Tempest seeks strategic alternatives as cash runs out for Phase 3 trial

Tempest seeks strategic alternatives as cash runs out f...

Apr 10, 2025  0

CDC vaccine meeting, set to be first since RFK Jr. sworn in, is postponed

CDC vaccine meeting, set to be first since RFK Jr. swor...

Feb 20, 2025  0

2Seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M

2Seventy bio, Bluebird’s cell therapy spinout, sells to...

Mar 11, 2025  0